supp.fit

Phosphatidylcholine: study protocols

27 study groups say how much Phosphatidylcholine participants took a day. These are the doses the studies gave. They are not a recommendation.

Phosphatidylcholine: what the research found →

Dose per serving from research

25 study groups in 19 studies say how much Phosphatidylcholine participants took a day.

These are the doses the studies gave. They are not a recommendation.

Most common: 2.5 g to 5 g, 32% of 25 study groups.

Daily doseStudy groups
250 mg to 500 mg
3
500 mg to 1 g
5
1 g to 2.5 g
4
2.5 g to 5 g
8
5 g to 10 g
2
10 g to 25 g
2
over 25 g
1

Commonly used together

2 of 27 study groups took Phosphatidylcholine with something else, but nothing that 3 or more different studies gave.

27 study groups

Study
[Non-alcoholic fatty liver disease of liver stagnation and spleen deficiency pattern treated with acupoint embedding therapy: a randomized controlled trial]
2016 · western medication group · People with non-alcoholic fatty liver disease of the liver stagnation and spleen deficiency pattern
684 mg26 weeks90
First multicenter study of modified release phosphatidylcholine "LT-02" in ulcerative colitis: a randomized, placebo-controlled trial in mesalazine-refractory courses
2014 · 0.8 g LT-02 group · Patients with mesalazine-refractory ulcerative colitis; age and sex not specified
800 mg12 weeks41
First multicenter study of modified release phosphatidylcholine "LT-02" in ulcerative colitis: a randomized, placebo-controlled trial in mesalazine-refractory courses
2014 · 1.6 g LT-02 group · Patients with mesalazine-refractory ulcerative colitis; age and sex not specified
1.6 g12 weeks40
First multicenter study of modified release phosphatidylcholine "LT-02" in ulcerative colitis: a randomized, placebo-controlled trial in mesalazine-refractory courses
2014 · 3.2 g LT-02 group · Patients with mesalazine-refractory ulcerative colitis; age and sex not specified
3.2 g12 weeks35
Retarded release phosphatidylcholine benefits patients with chronic active ulcerative colitis
2005 · phosphatidylcholine-treated group · Adults with chronic active, non-steroid-dependent ulcerative colitis and a clinical activity index of at least 4
6 g90 days30
Phosphatidylcholine for steroid-refractory chronic ulcerative colitis: a randomized trial
2007 · phosphatidylcholine recipients · Adults with chronic steroid-refractory ulcerative colitis and high clinical and endoscopic disease activity
2 g12 weeks30
Delayed release phosphatidylcholine in chronic-active ulcerative colitis: a randomized, double-blinded, dose finding study
2010 · 0.5 g daily group · Patients with chronic-active ulcerative pancolitis who were not receiving steroids
500 mg12 weeks10
Delayed release phosphatidylcholine in chronic-active ulcerative colitis: a randomized, double-blinded, dose finding study
2010 · 1 g daily group · Patients with chronic-active ulcerative pancolitis who were not receiving steroids
1 g12 weeks10
Delayed release phosphatidylcholine in chronic-active ulcerative colitis: a randomized, double-blinded, dose finding study
2010 · 3 g daily group · Patients with chronic-active ulcerative pancolitis who were not receiving steroids
3 g12 weeks10
Delayed release phosphatidylcholine in chronic-active ulcerative colitis: a randomized, double-blinded, dose finding study
2010 · 4 g daily group · Patients with chronic-active ulcerative pancolitis who were not receiving steroids
4 g12 weeks10
Effect of phosphatidylcholine on explicit memory
1993 · 10 g phosphatidylcholine · College students; age and sex not specified
10 g1 day—
Effect of phosphatidylcholine on explicit memory
1993 · 25 g phosphatidylcholine · College students; age and sex not specified
25 g1 day—
Perinatal choline effects on neonatal pathophysiology related to later schizophrenia risk
2013 · Choline group · Healthy pregnant women recruited in the second trimester and their infants; maternal age and infant sex range not stated
3.7 g244 days46
Polyenylphosphatidylcholine improves the lipoprotein profile in diabetic patients
1994 · PPC group · Adults with non-insulin-dependent diabetes and secondary hyperlipidemia
2.7 g60 days—
Choline supplementation for preterm infants: metabolism of four Deuterium-labeled choline compounds
2023 · D9-POPC · Preterm infants born at 28 0/7–32 0/7 weeks’ gestation, both sexes, receiving enteral feeds
2.7 mg/kg1 day8
Differential metabolism of choline supplements in adult volunteers
2022 · Egg-phosphatidylcholine (egg-PC) · Healthy adult men aged 18 years or older
4.02 g1 day6
Different choline supplement metabolism in adults using deuterium labelling
2023 · D9-POPC · Healthy adult men aged 26–65
18.6 mg/kg1 day6
Polyunsaturated phosphatidyl-choline and interferon alpha for treatment of chronic hepatitis B and C: a multi-center, randomized, double-blind, placebo-controlled trial. Leich Study Group
1998 · PPC group · Patients with chronic hepatitis B or C
1.8 g48 weeks92
A Multicenter and Randomized Controlled Trial of Bicyclol in the Treatment of Statin-Induced Liver Injury
2017 · polyene phosphatidylcholine group · Adults aged 24–66, any sex, with statin-induced liver injury and elevated ALT
1.37 g4 weeks78
Vitaphospholip® (water-soluble phosphatidylcholine) in the treatment of combined hyperlipidemia: a randomized, placebo-controlled clinical trial
2025 · Vitaphospholip® group · Patients with combined hyperlipidemia
1 g12 weeks39
[The effect of polyene phosphatidylcholine administration on lipid metabolism and glucose tolerance in patients with hyperlipoproteinemia IIB]
1995 · polyene phosphatidylcholine (PPC) · Patients with hyperlipoproteinemia type IIB and hypoalfacholesterolemia
2.7 g90 days30
Choline supplemented as phosphatidylcholine decreases fasting and postmethionine-loading plasma homocysteine concentrations in healthy men
2005 · phosphatidylcholine · Healthy men with mildly elevated plasma homocysteine concentrations
2.6 g2 weeks26
Dietary Choline Supplements, but Not Eggs, Raise Fasting TMAO Levels in Participants with Normal Renal Function: A Randomized Clinical Trial
2021 · phosphatidylcholine capsules · Healthy men and women aged 18 years or older with normal renal function
840 mg4 weeks—
Pharmacokinetics of soy-derived lysophosphatidylcholine compared with that of glycerophosphocholine: a randomized controlled trial
2024 · LPC supplementation · Healthy men; age not specified
480 mg1 day—
Effects of dietary fish oil and soy phosphatidylcholine on neutrophil fatty acid composition, superoxide release, and adhesion
1998 · group 2, soybean phosphatidylcholine · healthy volunteers matched for sex and age
25 g2 weeks—
Effect of homocysteine-lowering nutrients on blood lipids: results from four randomised, placebo-controlled studies in healthy humans
2005 · Study 4 phosphatidylcholine group · Healthy men aged 50–71 years with plasma homocysteine below 26 μmol/L
34 g2 weeks26
Effects of phytosomal curcumin on anthropometric parameters, insulin resistance, cortisolemia and non-alcoholic fatty liver disease indices: a double-blind, placebo-controlled clinical trial
2020 · Phytosomal curcumin · Adults aged 18–70 years with overweight (BMI 25–30 kg/m²) and suboptimal fasting plasma glucose (100–125 mg/dL)
480 mg8 weeks40